Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 11;20(1):4.
doi: 10.1186/s12944-020-01428-y.

Evaluation of cardiovascular risk factors in patients with familial hypercholesterolemia from the North-Eastern area of Romania

Cristiana-Elena Vlad  1   2 , Liliana Foia  3 , Laura Florea  1   2 , Irina-Iuliana Costache  2 , Andreea Covic  2 , Roxana Popescu  2 , Delia Reurean-Pintilei  2 , Adrian Covic  1   2   4
Affiliations

Evaluation of cardiovascular risk factors in patients with familial hypercholesterolemia from the North-Eastern area of Romania

Cristiana-Elena Vlad et al. Lipids Health Dis. .

Abstract

Background: Familial hypercholesterolemia(FH) is one of the most frequent and important monogenic cholesterol pathologies. Traditional and non-traditional cardiovascular risk factors increase the prevalence of atherosclerotic cardiovascular disease(ASCVD) in this population. The aims of the study were: (a) to identify FH patients in the North-Eastern part of Romania and to analyze demographic, clinical and paraclinical data (b) to evaluate the risk of new cardiovascular events at follow-up in FH patients stratified by lipid-lowering agents.

Methods: This first prospective study in the North-Eastern part of Romania was carried out between October 2017 and October 2019; out of 980 patients with dyslipidemia evaluated with the Dutch Lipid Network(DLCN) and Simon Broome(SM) scores, 61 patients with DLCN score above 3 and possible/probable FH(SM score) were included.

Results: Nine hundred-eighty patients were examined and 61 (6.2%) were received the clinical diagnosis of FH. The mean age was 48.5±12.5 years, with more female patients than male patients (63.9% versus 36%). Hypertension was the main cardiovascular risk factor for both genders, followed by physical inactivity and obesity for the female group and active smoking for the male group. The measured DLCN score recorded: "possible" FH identified in 39.4%, "probable" FH in 45.9% and "definite" FH in 14.7%. The effective lipid-lowering drugs used were statin alone and statin in association with fenofibrate, which improved both the lipid profile values and the subclinical atherosclerosis markers (ankle-brachial index, carotid intima-media thickness and high-sensitivity C-reactive protein). New ASCVDs that emerged during the study were most commonly represented by coronary heart disease and stroke. At the same time, the new cardiovascular events were delayed in patients receiving the lipid-lowering drugs, without significant differences between them.

Conclusions: In patients with suspected FH, the lipid-lowering agents during the follow-up period delayed the new cardiovascular events, yet failed to reach the goals proposed by the guidelines.

Keywords: Ankle-brachial index; Atherosclerotic cardiovascular disease; Cardiovascular risk factors; Carotid intima-media thickness; Familial hypercholesterolemia; Low density lipoprotein cholesterol.

PubMed Disclaimer

Conflict of interest statement

The author(s) declare(s) that there is no conflict of interest regarding the publication of this paper.

Figures

Fig. 1
Fig. 1
The frequency of FH patients according to a. age and b. gender
Fig. 2
Fig. 2
The frequency of the DLCN score and the distribution of the score by a. age and b. gender
Fig. 3
Fig. 3
Lipid profile (a. total cholesterol; b. LDL-C; c.HDL-C; d.TG; e.hsCRP) based on the lipid-lowering treatment and the effect of time interval
Fig. 4
Fig. 4
The frequency of the new ASCVD a. in population with clinical diagnosis of FH b. in this population by gender
Fig. 5
Fig. 5
Kaplan Meier for ASCVD depending on the lipid-lowering therapy and time interval for the occurrence of new cardiovascular events
See this image and copyright information in PMC

References

    1. Rahman T, Hamzan NS, Mokhsin A, Rahmat R, Ibrahim ZO, Razali R, et al. Enhanced status of inflammation and endothelial activation in subjects with familial hypercholesterolaemia and their related unaffected family members: a case control study. Lipids Health Dis. 2017;16(1):81. - PMC - PubMed
    1. Gragnano F, Calabro P. Role of dual lipid-lowering therapy in coronary atherosclerosis regression: evidence from recent studies. Atherosclerosis. 2018;269:219–228. - PubMed
    1. Watts GF, Gidding SS, Mata P, Pang J, Sullivan DR, Yamashita S, et al. Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. Nat Rev Cardiol. 2020;17(6):360–77. - PubMed
    1. Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):2425–2437. - PMC - PubMed
    1. Gidding SS, Champagne MA, de Ferranti SD, Defesche J, Ito MK, Knowles JW, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation. 2015;132(22):2167–2192. - PubMed